P-Glycoprotein (P-gp) may have a significant impact on systemic and tissue/cellular bioavailability of drugs because it functions as an "anti-absorption" mechanism that effluxes drug molecules out of the lipid bilayer and cytoplasm. The ability to reduce bioavailability at the tissue/cellular level was first discovered during the investigation of the causes of multidrug resistance (MDR) in cancer chemotherapy. Initially, it was thought that MDR is only caused by P-gp. Recently, many other transporters such as multidrug resistance-related protein (MRP) have also been identified. The ability of P-gp to impact systemic drug bioavailability was only recently recognized. Dr. Alfred Schinkel's group was first to show a significant improvement in the systemic bioavailability of several drugs in the MDR1 knockout mice. The same group also discovered that the blood-brain barrier (BBB) has a very high expression level of P-gp, and that this protein is necessary to restrict the entrance of various drug molecules into the central nervous system (CNS).
Introduction
P-Glycoprotein (P-gp) has been implicated in multidrug resistance (MDR), which is a major problem in cancer chemotherapy. In MDR tumor cells, P-gp tends to confer widespread resistance to a range of other drugs to which the cell was not exposed previously. These drugs can differ widely in chemical structure and in the mechanism by which they kill the cell from the original selecting drug. P-gp is also expressed by normal cells to protect the organism against the entry of xenobiotics. Among the vital organs expressing P-gp are intestine, liver, blood brain barrier (BBB), testes, and kidney. Since drugs are xenobiotics by nature, their bioavailability will be influenced by P-gp. Genetic polymorphisms of P-gp in humans have not been reported frequently but they may be important in influencing the outcome of pharmacotherapy. The focus of this article is the relationship between P-gp and bioavailability and how polymorphism in P-gp will be likely to impact on bioavailability.
P-Glycoprotein
The P-gp is a 1280 amino acid, glycosylated plasma membrane protein, which consists of two similar halves, each containing six putative transmembrane regions and 1 ATP binding site. It was first characterized as the ATP-dependent transporter responsible for efflux of chemotherapeutic agents from MDR cancer cells (1) (2) (3) . Substrates for P-gp cover a variety of chemical structures, and many of them are drugs with diverse therapeutic indications. There are no clear structural features defining P-gp substrates; however, the molecules are usually lipophilic and amphipathic, containing one or more aromatic rings. P-gp is the beststudied member of the ATP binding cassette (ABC) family of transporters. Other ABC transporters include a second P-gp coded by the MDR2 gene; multidrug resistance related proteins multidrug resistance-related protein (MRP) and MRP-2; bile salt export pump (BSEP); sodium bile acid co-transporter (Ntcp); and the organic anion transporter (Oatp)(4) which may also play important roles in drug bioavailability. P-gp is expressed in a broad spectrum of tissues including the adrenals, bladder, cells of blood-brain barrier, kidney, liver, lungs, pancreas, rectum, spleen, and, significantly for oral drug delivery, the esophagus, stomach, jejunum, and colon (2, 5, 6) . In apparent contrast to the observation for cytochrome P450 3A (CYP3A), the main phase I metabolic enzyme in the gut responsible for extrahepatic clearance of many drugs, P-gp mRNA levels increase along the intestine, with lowest level in the stomach and highest levels in the colon (5) . P-gp levels also show significant intersubject variability with 2-8 fold variations found in small intestinal biopsies from kidney transplant recipients and healthy volunteers (7) (8) (9) .
Models for Studying the Role of P-Glycoprotein
One of the most selective models to analyze the role of intestinal P-gp in vivo is the mdr1a -/-mouse (10). In contrast to humans, mice have two genes encoding P-gp: mdr1a and mdr1b (11) . The mdr1a -/-mouse completely lacks mdr1a P-gp due to a homozygous disruption of the mdr1a gene. By comparing the oral bioavailability of a drug between normal (wild-type) and mdr1a -/-mice, Schinkel et al. (10) found that mdr1a-/-mice are almost 100-fold more sensitive to orally administered ivermectin. In normal animals, the abundant P-gp in the blood-brain barrier pumps ivermectin efficiently out of the brain, but in mdr1a -/-mouse, this function is absent, resulting in almost 100-fold higher accumulation of ivermectin in the brain. They also found that P-gp in the blood-brain barrier limits the brain accumulation of many other drugs, including vinblastine, dexamethasone, digoxin, cyclosporin A, ondansetron, and loperamide (10, 12, 13) . The continuous accumulation of digoxin in the brain of mdr1a -/-mouse over a period of 3 days after a single intravenous administration contrasts sharply with the very low and gradually diminished levels in brains of wild-type mice. Apart from the highly increased brain penetration, the mdr1a -/-mouse also displayed a clearly delayed elimination of many drugs from plasma after intravenous administration of vinblastine, digoxin and cyclosporin A (10, (13) (14) (15) .
In vitro models may also be applied to study the functions of P-gp. Kim et al. (16) examined the transport characteristics of indinavir, nelfinavir and saquinavir, three human immunodeficiency virus protease inhibitors in the gut, using human Caco-2 cells and in vivo after intravenous and oral administration of these agents to mdr1a gene knockout mice. They found that all three protease inhibitors were MDR1 substrates. After oral administration of these inhibitors, their plasma concentrations in mdr1a -/-mouse increased 2-5 fold, suggesting that the presence of P-gp in the epithelial cells of the gastrointestinal tract limits the oral bioavailability of these compounds. The concentrations of HIV protease inhibitors in the brains of mdr1a -/-mice increased 7-36 fold after intravenous administration, indicating that P-gp limits the penetration of these agents in the brain. Sparreboom et al. (17) found that when paclitaxel was administered orally to mdr1a -/-mice, the oral bioavailability of this drug increased more than 3-fold. Wacher et al. (18) examined the effect of P-gp and CYP3A on limiting the oral absorption of peptides and peptidomimetics, and concluded that CYP3A and P-gp have a significant impact on their bioavailability. Inhibition of one or both of the systems can be expected to improve the bioavailability of many of these products and decrease the variability in observed systematic drug concentrations. Schinkel et al. (12) have shown that absence of the mouse mdr1a P-gp in mdr1a -/-mice has a profound effect on the tissue distribution, pharmacokinetics, and toxicity of a number of important pharmaceutical agents, including vinblastine, ivermectin, dexamethasone, digoxin, and cyclosporine. Koren et al. (19) attributed the toxic interaction of digoxin and many other drugs to P-gp in the renal tubular cells.
Clinical Data and Implications
Clinical studies have suggested that P-gp may limit the oral absorption of substrate drugs. Oral bioavailabilities of cyclosporin A and tacrolimus were shown to increase substantially after cotreatment with ketoconazole, which was attributed to mainly the inhibitory effect of ketoconazole on intestinal cytochrome P450 (CYP) enzymes and P-gp (20) (21) (22) . Fricker et al. (23) administered cyclosporin A in different parts of the gastrointestinal tract of human subjects and found a strong negative correlation between the extent of absorption and the local mRNA levels of P-gp. When the relationship between oral pharmacokinetic parameters of cyclosporin A and the level of P-gp in the intestines were examined in renal transplant recipients (24) it was found that intestinal P-gp might play a significant role in limiting the oral absorption of cyclosporin A. Lown et al. (8) also studied the impact of P-gp on cyclosporine absorption in stable kidney graft recipients, and found that hepatic metabolism accounted for 56% of the interpatient variability in apparent oral clearance (Cl oral ) and 32% of the variability in C max , whereas intestinal P-gp accounted for 17% of the variability in Cl oral and 30% of the variability in C max . Intestinal CYP3A did not provide any additional predictability of cyclosporin clearance or C max in this model.
The blockade of intestinal P-gp may decrease the elimination of an intravenously administered substrate drug as a consequence of an increased re-uptake from the intestinal lumen and/or a diminished intestinal secretion. A decreased total body clearance of an intravenously administered P-gp substrate drug has been observed frequently after co-treatment of patients with a reversal agent. For example, the total body clearance of digoxin and paclitaxel were found to decrease substantially after co-treatment of human subjects with verapamil (25, 26) . Similarly, co-administration of the reversal agent nifidipine reduced the total body clear-ance of vincristine (27) , and co-treatment of patients with cyclosporin A resulted in a decreased renal and non-renal clearance of etoposide (28) . The decreased renal clearance observed demonstrated that mechanisms other than inhibition of intestinal P-gp could also contribute to the diminished drug elimination of patients co-treated with a reversal agent (28) . A blockade of P-gp in the liver and the kidney may reduce the biliary and renal secretion of substrate drugs, respectively. Although the vast majority of the literature have emphasized the bioavailability-enhancing effects of Pgp inhibitors, a few studies have produced contradictory results. For example, Schwarz et al. (29) showed a slight decrease in oral bioavailability of talinolol in humans as a result of co-administration of R-verapamil. This effect is assumed to be caused by changes of the intestinal net absorption of talinolol because its renal clearance remains unaffected by administration of Rverapamil. This unexpected effect of verapamil is most likely dose-dependent as a result of interplay between intestinal P-gp and gut metabolism. Contrary to the results of oral dosing studies, Gramatte and Oertel (30) have found that the intravenously administered talinolol is actively secreted into the human small intestine, and the secretion is reduced by the intraluminal supply of P-gp modulating drug verapamil. Taken together, it is not too difficult to speculate that multiple transporters might be involved in the absorption and secretion of talinolol.
The metabolic inhibition is likely to occur concurrently with P-gp inhibition, since many compounds interacting with P-gp (subtrates or inhibitors) are substrates for the CYP3A (e.g. paclitaxel, verapamil, nifidipine, vincristine, cyclosporin A and etoposide) (31). This is not entirely surprising since it is widely speculated that P-gp and CYP3A may have complementary roles in limiting oral bioavailability (28) . In addition, there are also some indications that the levels of these proteins are coordinately regulated (13, 28 ) , but this remains controversial (24) .
The blockade of P-gp and inhibition of CYP3A is an attractive strategy for improving the oral bioavailability of substrate drugs in patients. Indeed, several clinical studies discussed above have already demonstrated that the oral bioavailability of a drug can be enhanced by co-administration of a reversal agent (20, 21) . Moreover, this concept may also offer new opportunities to develop clinically useful oral formulations of drugs that are not currently administered orally because of poor oral absorption. This is confirmed by preclinical studies, which clearly showed that the systemic exposure to orally administered paclitaxel significantly increased when mice were pretreated with SDZ PSC 833 or cyclosporin A (32, 33) . Furthermore, a recent clinical study provided "the proof of concept"; a substantially increased systemic exposure to orally administered paclitaxel was observed in patients cotreated with cyclosporin A (34) . However, it is important to stress that a reversal agent will probably not only inhibit P-gp in the intestines but also in other tissues, which may result in an increased potential or altered spectrum of adverse effects of the administered drugs. For example, inhibition of P-gp in the blood-brain barrier may increase the drug accumulation in the brain and thereby augment the risk of central neurotoxicity (15) .
Polymorphism of P-gp
Polymorphism of P-gp has only been sporadically reported in literature with the majority of the literature coming from mutation of P-gp in cancer cells (35, 36) . The majority of the information came from artificial mutation of P-gp through molecular biology techniques or through selection media using culture cells. A subpopulation of the CF-1 mouse has natural expression of functionally deficient P-gp (37), and they are often more susceptible to drug-induced neurotoxicity (37) , and are at higher risk of birth defects caused by chemicals (38) . Several mutations of human P-gp have been reported but their functional implications remain sketchy. There are some correlations between certain P-gp polymorphism types and bioavailability of digoxin as reported by Hoffmeyer et al. (36) , but the study did not account for metabolism differences.
Conclusion
In the setting of increased attention to patient qualityof-life issues, orally formulated chemotherapy is preferred by the patients provided that equal efficacy can be maintained (39) . The efficacy of oral chemotherapy is contingent upon overcoming numerous bioavailability barriers at the absorption site, in the liver and at the target organs. P-gp is a major barrier to the entry of xenobiotics. Although P-gp is certainly not the only determinant of oral availability, for some drugs it may be the most prominent determinant. In principle, intestinal P-gp could be inhibited by oral administration of an effective reversal agent, which should lead to an increased oral bioavailability of a coadministered drug. Several inhibitors of P-gp are currently on the clinical trial stage and several natural inhibitors of P-gp have been discovered. Lastly, polymorphism in P-gp is likely to occur because of the mutation frequency we have observed in malignant cells. Although presently available information do not demonstrate that this polymorphism is critically important for pharmacotherapy, our enhanced understanding of this transporter will undoubtedly lead to better therapeutic outcomes in the future. These new developments should have significant impact on the bioavailability of a variety of anticancer and central nervous system drugs in the next decades and beyond.
